215 results on '"Zignego, A.L."'
Search Results
2. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C
3. Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus
4. Hepatitis C virus core protein enhances B lymphocyte proliferation
5. HCV-related autoimmune and neoplastic disorders: the HCV syndrome
6. Hepatitis C virus lymphotropism: lessons from a decade of studies
7. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach
8. Cryoglobulins. (Review)
9. Genetic and B-cell clonality markers in HCV-related cryoglobulinemic vasculitis persisting after DAA therapy
10. Cryoglobulinaemia
11. IGG subclasses, free light chains and vascular endothelial growth factor in HCV-related mixed cryoglobulinemic syndrome
12. A novel biomarkers score for the screening and management of patients with plasma cell proliferative disorders
13. P.04.20 LONGITUDINAL EVALUATION OF LIVER FIBROSIS AND OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C UNDERGOING IFN-FREE ANTIVIRAL TREATMENT
14. Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers
15. Extracellular vesicles derived from CHK2 mRNA as a possible predictive marker of HCC in HCV-infected patients
16. Anti-hepatitis a virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis
17. Extrahepatic Manifestations of Hepatitis C Virus Infection
18. Chronic hepatitis C and B-cell non-Hodgkin's lymphoma
19. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
20. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection
21. Non-invasive B-cell clonality markers may help in the rational approach to HCV SVR cryoglobulinemic patients with persisting manifestations
22. Forecasting liver disease burden
23. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV
24. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement
25. Second generation direct-acting antiviral (DAAs) Treatment on HCV+ patients: Patient reported outcomes (PROs) and psychiatric symptoms in a real world setting sample
26. Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)
27. Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life
28. Sustained virological response in HCV patients treated with daclatasvir + sofosbuvir, with or without ribavirin: a multicenter, field-practice experience
29. Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort
30. New interferon-free therapies on HCV+ chronic hepatitis: Overcoming psychiatric side effects in a real world setting
31. High SVR rates with SMV+SOF in HCV GT1 and GT4 patients with cirrhosis or advanced fibrosis: A real practice analysis from a large regional database in Tuscany, Italy
32. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study
33. High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy
34. Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study
35. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study
36. HCV infection, malignancy, and liver transplantation
37. Preliminary classification criteria for the cryoglobulinaemic vasculitis
38. Strategie terapeutiche nella crioglobulinemia mista: recenti acquisizioni
39. OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins
40. P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases
41. O060 : MIR-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia
42. Coping with Neuropsychiatric Side Effects of Pegylated Interferon Alpha Therapy in Hepatitis C Virus Positive (HCV+) Patients: an Observational Study.
43. Mir-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia
44. Assessment of free light chains in HCV positive patients with mixed cryoglobulinemia vasculitis undergoing rituximab treatment
45. Notch4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases
46. OP0228 Rituximab Monotherapy of Severe Hcv-Related Cryoglobulinemic Vasculitis for More than 2 Years: Follow-Up of A Randomized Controlled Multicentre Study
47. P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM
48. Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey
49. Mixed cryoglobulinemia, lymphomas and HCV
50. SAT-144 - High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.